Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors — a major reason for enhanced chemosensitivity?

Chinese Journal of Cancer Research

Volumn 29, Issue 4, 2017, Pages 374-378

  Shenoy, Niraj ^a   Dronca, Roxana ^a   Quevedo, Fernando ^a   Boorjian, Stephen A ^a   Cheville, John ^a   Costello, Brian ^a   Kohli, Manish ^a   Witzig, Thomas ^a   Pagliaro, Lance ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemosensitivity; Hypoxia inducible factor 1 (HIF 1 ); Testicular germ cell tumor

Indexed keywords

EID: 85028469699     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.21147/j.issn.1000-9604.2017.04.11     Document Type: Article

References (36)

1. Vranic S, Hes O, Grossmann P, et al. Low frequency of HIF-1α overexpression in germ cell tumors of the testis. Appl Immunohistochem Mol Morphol 2013;21:165-9.
2. Mayer F, Honecker F, Looijenga LH, et al. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 2003;14:825-32
3. Voutsadakis IA. The chemosensitivity of testicular germ cell tumors. Cell Oncol (Dordr) 2014;37:79-94.
4. Mayer F, Stoop H, Scheffer GL, et al. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 2003;9:767-73.
5. Masters JR, Thomas R, Hall AG, et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 1996; 32A: 1248-53.
6. Koropatnick J, Kloth DM, Kadhim S, et al. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J Pharmacol Exp Ther 1995;275:1681-7.
7. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148:877-87.
8. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2014;2:3.
9. Lu H, Samanta D, Xiang L, et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A 2015;112:E4600-9.
10. Zhu H, Chen XP, Luo SF, et al. Hypoxia-inducible factor-1 alpha dependent expression and significance of the related multidrug resistance genes induced by hypoxia in human hepatocarcinoma cell. Zhonghua Wai Ke Za Zhi (in Chinese) 2005;43:277-81.
11. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-94.
12. Köberle B, Masters JR, Hartley JA, et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-6.
13. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996;88:1346-60.
14. Matsuda T, Saijo M, Kuraoka I, et al. DNA repair protein XPA binds replication protein A (RPA). J Biol Chem 1995;270:4152-7.
15. Buschta-Hedayat N, Buterin T, Hess MT, et al. Recognition of nonhybridizing base pairs during nucleotide excision repair of DNA. Proc Natl Acad Sci U S A 1999;96:6090-5.
16. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8.
17. Liu Y, Bernauer AM, Yingling CM, et al. HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 2012;33:1187-92.
18. Sermeus A, Genin M, Maincent A, et al. Hypoxiainduced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PLoS One 2012;7:e47519.
19. Chen N, Chen X, Huang R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1. J Biol Chem 2009;284:10004-12.
20. Kilic M, Kasperczyk H, Fulda S, et al. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007;26:2027-38.
21. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxiamediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
22. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
23. Palayoor ST, Mitchell JB, Cerna D, et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008;123:2430-7.
24. Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009;8:947-58.
25. Jiao M, Nan KJ. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelialmesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 2012;40:461-8.
26. Fischer C, Leithner K, Wohlkoenig C, et al. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. Mol Cancer 2015;14:4.
27. Chen J, Ding Z, Peng Y, et al. HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One 2014;9:e98882.
28. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
29. Yeom CJ, Zeng L, Zhu Y, et al. Strategies to assess hypoxic/HIF-1-active cancer cells for the development of innovative radiation therapy. Cancers (Basel) 2011;3:3610-31.
30. Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol 2016;27:1685-95.
31. Shenoy N, Shrivastava M, Sukrithan V, et al. The regulation and interactions of the hypoxia inducible factor pathway in carcinogenesis and potential cancer therapeutic strategies. J Cancer Ther 2015;6:511-21.
32. Xing T, He H. Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res 2016;28:80-91.
33. Rao Q, Xia QY, Cheng L, et al. Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res 2016;28:29-49.
34. Schwartz DL, Bankson JA, Lemos R Jr, et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010;9:2057-67.
35. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009;13:2780-6.
36. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14: 34-44.